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Abstract
Background: 4-hydroxy-2-oxoglutarate (HOG) aldolase is a unique enzyme in the hydroxyproline degradation pathway
catalyzing the cleavage of HOG to pyruvate and glyoxylate. Mutations in this enzyme are believed to be associated with the
excessive production of oxalate in primary hyperoxaluria type 3 (PH3), although no experimental data is available to support
this hypothesis. Moreover, the identity, oligomeric state, enzymatic activity, and crystal structure of human HOGA have not
been experimentally determined.
Methodology/Principal Findings: In this study human HOGA (hHOGA) was identified by mass spectrometry of the
mitochondrial enzyme purified from bovine kidney. hHOGA performs a retro-aldol cleavage reaction reminiscent of the
trimeric 2-keto-3-deoxy-6-phosphogluconate aldolases. Sequence comparisons, however, show that HOGA is related to the
tetrameric, bacterial dihydrodipicolinate synthases, but the reaction direction is reversed. The 1.97 A ˚ resolution crystal
structure of hHOGA bound to pyruvate was determined and enabled the modeling of the HOG-Schiff base intermediate and
the identification of active site residues. Kinetic analyses of site-directed mutants support the importance of Lys196 as the
nucleophile, Tyr168 and Ser77 as components of a proton relay, and Asn78 and Ser198 as unique residues that facilitate
substrate binding.
Conclusions/Significance: The biochemical and structural data presented support that hHOGA utilizes a type I aldolase
reaction mechanism, but employs novel residue interactions for substrate binding. A mapping of the PH3 mutations
identifies potential rearrangements in either the active site or the tetrameric assembly that would likely cause a loss in
activity. Altogether, these data establish a foundation to assess mutant forms of hHOGA and how their activity could be
pharmacologically restored.
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Introduction
Glyoxylate is a highly reactive two carbon anion and
traditionally thought to be produced through glycine and glycolate
metabolism [1–4]. Recent studies, however, have demonstrated
that significant glyoxylate and oxalate production can occur
through the metabolism of 4-hydroxyproline (4-Hyp). It is
estimated that 300–450 mg of 4-Hyp are produced each day
from endogenous collagen turnover, and additional 4-Hyp is
derived from the diet [5]. Since less than 30 mg of 4-Hyp is
excreted in the urine, the majority of 4-Hyp is metabolized in the
liver and kidney [6]. The degradation pathway for 4-Hyp
(Figure 1) involves the step-wise action of four mitochondrial
enzymes: hydroxyproline oxidase (HPOX), D
1-pyrroline-5-car-
boxylate dehydrogenase (1P5CDH), aspartate aminotransferase
(AspAT), and 4-hydroxy-2-oxoglutarate aldolase (HOGA, EC
4.1.3.16; also known historically as 2-keto-4-hydroxyglutarate
aldolase and 4-hydroxy-2-ketoglutarate aldolase) [5,7,8]. The first
three steps involve the oxidation of the 4-Hyp ring to D
1-pyrroline-
5-carboxylate, spontaneous ring opening and further oxidation,
and the conversion of 4-hydroxy-glutamate to 4-hydroxy-2-
oxogluarate (HOG). In the terminal reaction, HOG is cleaved
by HOGA to produce pyruvate and glyoxylate. The resulting
glyoxylate can be converted to glycine and glycolate by alanine-
glyoxylate aminotransferase (AGT) and glyoxylate reductase (GR),
respectively. Thus, in normal metabolism, the glyoxylate produced
from 4-Hyp is readily detoxified.
In contrast, patients with primary hyperoxaluria (PH) can have
dysfunctional AGT (PH type 1) or GR (PH type 2) [9]. As a result,
glyoxylate levels rise and oxalate can be produced by lactate
dehydrogenase (LDH) (Figure 1), ultimately resulting in the
formation of calcium oxalate kidney stones [10,11]. Therefore,
the glyoxylate produced from 4-Hyp most likely exasperates the
glyoxylate and oxalate levels of PH patients. A recent report using
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unclassified form of PH identified mutations in the DHDPSL gene
[12]. Several additional mutations have subsequently been
identified [13]. It was speculated that this gene is human HOGA,
and a proposal was made to reclassify these patients as having PH
type 3 (PH3). Direct evidence for the enzymatic activity of the
DHDPSL gene product, however, was not obtained. Moreover,
despite the greater than 40 years of work in delineating the 4-Hyp
degradation pathway utilizing HOGA purified from bovine and
rat mitochondria, the identity, oligomeric state, enzymatic activity,
and crystal structure of human HOGA (hHOGA) have not been
experimentally determined [8,14–18].
The identification of HOGA mutations clearly highlights the
need to better understand 4-Hyp metabolism in humans and raises
many potential scenarios for increased oxalate formation. In one
proposal the mutations found within hHOGA are thought to
increase enzymatic activity and glyoxylate production, which
would be consistent with the phenotypes observed in PH1–3
patients [9,12,13]. Alternatively, the HOGA variants could have
decreased enzymatic activity, aberrant cellular targeting, and
decreased stability. If any of these scenarios are correct, HOG
could build up in concentration, but the physiological conse-
quences are currently unknown. Experiments to determine the
molecular basis for human HOGA substrate recognition and
catalysis are therefore needed to evaluate the potential impact of
mutations found in PH3 patients.
The work presented herein describes the identification of
hHOGA by mass spectrometry of bovine HOGA purified from
kidney mitochondria. The activity of recombinant hHOGA proves
that it is indeed the aldolase identified in the genomic analysis of
PH3 patients. The crystal structures of the apoenzyme and
pyruvate-Schiff base intermediate complex are the first for any
HOGA enzyme to date and reveal a tetrameric structure
composed of a dimer of dimers as well as the identity of active
site residues. Kinetic analyses of site-directed mutants have shown
that Tyr168 and Lys196 are essential for catalysis, while Ser77,
Asn78, and Ser198 appear to modulate substrate binding and
catalysis. The mapping of the PH3 mutations suggests that some
variants impact the active site architecture and others affect the
oligomeric state. Altogether, these data provide new insights into
the mechanism of hHOGA and a structural blueprint to assess the
activity of mutant forms of hHOGA and their potential rescue.
Results
The 4-Hyp catabolic pathway (Figure 1) has been delineated
through the fractionation and characterization of mitochondrial
lysates from the liver and kidney tissues of several mammals [8,14–
18]. The last step of the pathway, the cleavage of HOG to
pyruvate and glyoxylate by HOGA, is of particular importance to
PH patients where glyoxylate can be shunted to oxalate formation
[4]. Thus, modulation of 4-Hyp degradation has the potential to
ameliorate the production of glyoxylate from both endogenous
and dietary sources of 4-Hyp [11,19].
Purification of bovine HOGA enables identification of
human HOGA
In order to identify hHOGA, mitochondria were purified from
freshly dissected, bovine kidney cortex. Using a procedure adapted
from Dekker et al., bHOGA was purified using heat denaturation,
ammonium sulfate fractionation, anion exchange chromatogra-
phy, and size-exclusion chromatography (Figure 2A) [15]. During
this process the fractions containing aldolase activity, i.e.,
production of glyoxylate from HOG synthesized in-house (see
Experimental Procedures), were determined with a phenylhydra-
zine assay [14,20,21]. The HOG used in these studies is a racemic
mixture. Previous studies have shown that the bovine kidney,
bovine liver, and rat liver enzymes have equal activity against the
R- and S-forms of HOG [15,18,22]. The specific activity of
bHOGA increased with each purification step to 0.2 mmol
glyoxylate min
21 mg
21, representing a ,46,000-fold purification
(data not shown). The final yield of bHOGA was 1.9 mg.
The bHOGA protein was digested with trypsin and the
resulting peptide fragments analyzed by LC-MS/MS. Eight
peptides, representing 43.7% sequence coverage, were found to
match a bovine protein (Q0P5I5), annotated as a mitochondrial
Figure 1. Metabolism of 4-hydroxyproline and glyoxylate. Four
mitochondrial enzymes are responsible for 4-hydroxproline (4-Hyp)
breakdown: hydroxyproline oxidase (HPOX), D
1-pyrroline-5-carboxylate
dehydrogenase (1P5CDH), aspartate aminotransferase (AspAT), and 4-
hydroxy-2-oxoglutarate aldolase (HOGA). The terminal HOGA reaction
cleaves 4-hydroxy-2-oxoglutarate (HOG) into pyruvate and glyoxylate.
Glyoxylate is metabolized either to glycolate by glyoxylate reductase
(GR) in the mitochondria and cytoplasm or to glycine by peroxisomal
alanine-glyoxylate aminotransferase (AGT). AGT and GR are mutated
within primary hyperoxaluria (type 1 and 2, respectively) patients
resulting in the buildup of glyoxylate and its conversion by lactate
dehydrogenase (LDH) to oxalate, a key component of kidney stones.
doi:10.1371/journal.pone.0026021.g001
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intact bHOGA revealed that the mature form of the protein
begins at residue 26 (327 amino acids, 35,217 Da), and that the
protein as purified contains no additional posttranslational
modifications. The human HOGA homolog (NP_612422) was
readily identified by a BLAST search, and an IRAT clone was
obtained from Invitrogen. In order to clarify the many historical
names used for HOGA, the gene and protein sequence databases
have been updated to the following nomenclature HOGA1
(NM_138413) and HOGA1, respectively.
Human HOGA is related to bacterial DHDPS enzymes
A survey of the literature reveals that the reaction catalyzed by
HOGA (Figure 3) is most similar to the bacterial 2-keto-3-deoxy-
phosphogluconate aldolase (KDPGA) and related bacterial
aldolases [23–25]. These enzymes cleave their substrate and
produce pyruvate as the common product. Biochemical and
structural studies have shown that these enzymes function in a
trimeric assembly (Figure S1, A and B). The active site contains
conserved Arg17, Glu40, Lys129 and Thr156 residues (numbering
for the Thermatoga maritima enzyme) that facilitate catalysis and
formation of a Schiff base intermediate with the Lys residue [24].
Human and bovine HOGA both contain a conserved Lys196
(Figure 2B), but none of the other residues of the KDPGA active
site motif.
A BLAST search revealed that hHOGA was actually most
related to the dihydrodipicolinate synthase (DHDPS) from Bacillus
anthracis (Figure 2B, 31.1% identity). The DHDPS enzymes
perform a condensation reaction between pyruvate and (S)-
aspartate-b-semialdehyde to yield (4S)-4-hydroxy-2,3,4,5,-tetrahy-
dro-(2S) dipicolinate (HTPA), an unstable intermediate thought to
undergo dehydration to (S)-2,3-dihydropicolinate [26–29]. Since
this reaction is the first committed step in lysine biosynthesis, the
DHDPS enzymes are an attractive antibacterial target. In contrast
to KDPGA, these enzymes function as a tetrameric assembly
(Figure S1, C and D). The active site of E. coli DHDPS contains
five conserved residues, Thr44, Thr45, Tyr107, Tyr133, and
Lys161, as illustrated by the pyruvate-Schiff base adduct structure
(Figure S1D) [28]. The Tyr and Lys residues appear to be
conserved in human and bovine HOGA: Tyr140, Tyr168, and
Lys196 (Figure 2B).
Solution behavior of recombinant hHOGA
In order to characterize the solution, kinetic, and structural
properties of human HOGA, the gene was subcloned into the
pET151/D-TOPO vector so that the mitochondrial targeting
sequence was removed (i.e., residues 1–25). The protein was
expressed recombinantly in E. coli and readily purified using an N-
terminal His-tag and two additional column steps (Figure 2A).
Removal of the His-tag by limited proteolysis did not affect the
activity of the protein, but its removal did prevent aggregation at
higher protein concentrations (data not shown). One peculiar
observation from the purification warrants mention. During the
size-exclusion Superdex 200 column run, the peak containing
hHOGA eluted with a retention time midway between those
calculated for trimeric and tetrameric assemblies (Figure S2), an
apparent contradiction to the predicted tetramer based on the
similarity to the DHDPS enzymes. Perhaps hHOGA has some
intrinsic affinity for the Superdex 200 bead material despite the
presence of 100 mM NaCl in the elution buffer.
Sedimentation equilibrium ultracentrifugation data were col-
lected at three concentrations for the His-tag free protein (e.g.,
0.43, 0.82, and 1.25 mg ml
21) and two rotor speeds (7,500 and
10,500 g) to investigate this discrepancy (Figure 4A). The
simultaneous fit of these data and those obtained in a replicate
experiment (0.45, 0.78 and 1.14 mg ml
21) using HETEROANA-
LYSIS yielded a weight-average molecular weight, Mw,o f
97,2006810, a value 3-fold greater than that for a monomeric
species, but considerably less than a tetramer (130,500). Further
analysis using monomer-dimer-tetramer and dimer-tetramer
Figure 2. Identification of human HOGA and its sequence relationship to DHDPS enzymes. (A) SDS-PAGE analysis of bovine HOGA
purified from kidney and human HOGA expressed in E. coli. Lane 1, bovine HOGA; lane 2, human HOGA with an N-terminal, 6-His tag; lane 3, protein
molecular weight ladder indicated in kDa. (B) Sequence comparison of human HOGA with bovine HOGA (90.2% identity), B. anthracis DHDPS (31.1%),
M. tuberculosis DHDPS (26.6%), and E. coli DHDPS (22.3%). Putative catalytic residues for hHOGA (Tyr140, Tyr168, and Lys196) are indicated by green
circles. Blue circles indicate additional active site residues that were assessed by site-directed mutagenesis to evaluate their contribution to substrate
specificity and catalysis. HOGA mutations identified within PH3 patients are denoted with orange circles [12,13].
doi:10.1371/journal.pone.0026021.g002
Human HOGA and Primary Hyperoxaluria Type 3
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26021models (HETEROANALYSIS and SEDPHAT, Figure S3)
supports that a dimer-tetramer equilibrium is favored with a
calculated Kd value of ,60 mM [30]. The behavior of the His-tag
free hHOGA was also analyzed by dynamic light scattering. A
single mono-disperse peak (Figure S4) was obtained from solutions
containing 0.25–25 mg mL
21 hHOGA. While the peak diameter
(9.160.5 nm) is larger than that calculated for a globular trimer
(6.7 nm) or tetramer (7.3 nm), asymmetry or increased hydration
may contribute to this discrepancy. The prolate ellipsoidal, ring-
like shape of the bacterial DHDPS enzymes (Figure S1C) and
hHOGA, described in detail below, supports these possibilities.
Crystal structure of human HOGA
In an effort to clarify the oligomeric state of hHOGA, to
visualize the active site, and to determine the context of PH3
mutations, the structure of hHOGA was determined. A number of
crystallization conditions were identified using commercial screens
and the vapor diffusion technique. However, only one of these
conditions upon optimization produced strongly diffracting
crystals. A 2.5 A ˚ resolution dataset was collected for the native
apoenzyme at the National Synchrotron Light Source, beamline
X25 (Table 1). The inclusion of 10 mM pyruvate during
crystallization improved diffraction substantially and allowed for
in-house data collection to 1.97 A ˚ resolution. The crystals belong
to space group P6422 with the Matthew’s coefficient indicating 2
molecules per asymmetric unit (a.s.u.) and 50% solvent content.
Structure solution was first attempted using a monomer and
dimer of B. anthracis DHDPS (PDB ID: 1XKY, 31% sequence
identity) (Figure S1) as a molecular replacement search model
within PHASER [31]. Despite trying a variety of permutations
and adjustments to the search model to maximize homology (i.e.,
the use of CHAINSAW within CCP4i to prune non-conserved
side chains and the removal of surface loops), this approach failed
to provide a reasonable solution. Experimental phases were
determined from crystals containing hHOGA pre-derivatized with
the mercury-containing compound EMTS (Table 1). Using the
anomalous Hg
2+ signal, PHENIX identified 3 high-occupancy
sites that yielded readily interpretable 2.1 A ˚ resolution electron
density maps (Figure S5A). The AutoBuild routine within
PHENIX was able to build 97% of the structure. Interestingly,
the packing of hHOGA within the unit cell (Figure S5B) supports
only one molecule in the a.s.u. and a solvent content of 75%. The
crystallographic symmetry, however, does generate a tetramer that
rotates up the 3-fold screw axis, resulting in large solvent channels.
Figure 3. Comparison of the HOGA, KDPGA, and DHDPS reactions. The utilization of a Lys residue and Schiff base intermediate with
pyruvate for catalysis is shared between the enzymes. However, the preferred reaction directions are opposite, i.e., HOGA and KDPGA perform
cleavage reactions, while the DHDPS enzymes utilize a condensation reaction between pyruvate and (S)-aspartate-b-semialdehyde to form (4S)-4-
hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinate (HTPA). The wavy bond on the 4-position of HOG indicates that the enzyme can cleave both the S- and R-
forms of HOGA [15,18,22].
doi:10.1371/journal.pone.0026021.g003
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29.5%, and then used as a molecular replacement search model to
solve the structures of the apoenzyme and the Schiff base adduct
with pyruvate. Of the 302 residues in the mature form of hHOGA,
296 were modeled for both structures. No electron density was
observed for the first six residues of hHOGA and the three
residues remaining from the affinity tag. The final structures for
the apoenzyme and Schiff base adduct exhibited Rwork/free values
of 21.2/24.6% and 19.6/21.6%, respectively, and were of high
overall quality, as indicated by the refinement statistics in Table 1.
As mentioned briefly above, the crystallographic symmetry of
the hHOGA crystals generate a tetrameric assembly (Figure 5A
and Figure S5) containing a dimer of dimers. Residues 26–259
form an (a/b)8 TIM barrel domain, while residues 260–327 form
a three-helical bundle at the C-terminus (Figure 5B). The dimer-
dimer or ‘‘loose’’ interface (orange versus gray in Figure 5A)
primarily involves the interactions between the four helical
bundles, as described within the DHDPS literature [32–34]. In
contrast, the active site is located at the C-terminal end of the TIM
barrel domain near the monomer-monomer interface of the
‘‘tight’’ dimer (colored different shades of orange and gray in
Figure 5A). This interface involves many surface loops, one of
which protrudes into the active site of the adjacent monomer.
An omit Fo-Fc map contoured to 6.4 s shows clear continuous
electron density for the imine Schiff base adduct between the e-
amino group of Lys196 and pyruvate (Figure 6A). In this binding
mode, hydrogen bonding interactions are observed between the
hydroxyl group of Tyr168 and the O
(1B) carboxylate oxygen atom
of pyruvate (Figure 6B). Additional hydrogen bonding interactions
are present between the backbone amide nitrogen atoms of Ser77
and Asn78 and the O
(1B) and O
(1A) atoms of pyruvate, respectively.
A network between Ser77, Tyr168, and Tyr140’ from the adjacent
monomer is also formed. A superposition of the apoenzyme
structure with the pyruvate adduct (RMSD =0.19 A ˚ for Ca
atoms) reveals no significant structural changes to the active site
other than a water molecule within hydrogen bonding distance to
Lys196 (Figure 6B).
Assessment of putative catalytic residues
A superposition of hHOGA and E. coli DHDPS monomers in
complex with pyruvate (Figure 7A) confirms the overall structural
homology (RMSD =1.7 A ˚ for Ca atoms). The Schiff base adducts
and the surrounding active site residues also overlay well. The
same hydrogen-bonding network involving the two Tyr residues
(Tyr1409/1079 from the adjacent monomer and Tyr168/133; the
second residue number is for E. coli DHDPS), two backbone amide
nitrogen atoms (Ser77/Thr44 and Asn78/Thr45), and the side
chain of Ser77/Thr44 appear to be maintained with minor
adjustments. Ser77 of hHOGA is present within a conserved G-X-
X-G-E loop motif, where X is a variety of amino acids (Gly76-
Ser77-Asn78-Gly79-Glu80 in hHOGA). This motif is found
within all DHDPS enzymes [26–29,35]. Interestingly, Ser77
interacts with both Tyr168 and Tyr140’.
In order to test whether hHOGA utilizes the same catalytic
residues as the DHDPS enzymes, site-directed mutants for
Tyr140, Tyr168, Lys196 and Ser77 (Figure 7A) were generated
and purified. Circular dichroism analysis (Figure 4B) showed that
all the hHOGA variants had similar spectra. Secondary structure
index calculations showed that each mutant agrees within 10% of
wild-type hHOGA, supporting that these mutations did not cause
gross structural changes. The kinetic parameters for these variants
were readily determined using a coupled assay that relied upon the
consumption of NADH and the conversion of pyruvate to lactate
by LDH (Figure S6).
The Y140F mutant of hHOGA, evaluating a residue that
protrudes into the active site from the adjacent monomer
(Figure 7A), showed activity (Table 2) directly comparable to the
WT enzyme with kcat, KM and kcat/KM values of 5.2 s
21,8mM,
and 650 mM
21 s
21, respectively. This observation contrasts with
the comparable Y107F variant of E. coli DHDPS that resulted in
an 12-fold decrease in kcat [35]. The Y168F and K196A hHOGA
variants exhibited no enzymatic activity, even with 1,500 nM
enzyme and 450 mM HOG present in the reaction. These
significant losses in activity are similar to the 177-fold and
1,127-fold decreases in kcat observed for the same variants of E. coli
DHDPS [35]. The S77A variant exhibited a 2-fold decrease in kcat
and a nearly 8-fold increase in the KM value for HOG compared
to the WT enzyme (Table 2), resulting in an 20-fold reduction in
the catalytic efficiency (kcat/KM). The mutation of Ser77 to Thr, in
order to mimic the DHDPS enzymes, also caused a significant loss
in activity. A 50-fold decrease in kcat/K M, with a comparable
reduction and increase in kcat and KM, was observed, respectively.
A third mutant at this residue, S77V, was analyzed to simulate the
bulk of the Thr residue, but without the hydroxyl group
Figure 4. Characterization of recombinant hHOGA variants. (A)
Representative analytical ultracentrifugation analysis of His-tag free
HOGA at one rotor speed (10,500 rpm) and three different concentra-
tions: black triangles, 1.25 mg ml
-1; gray squares, 0.82 mg ml
21; open
circles, 0.43 mg ml
21. The solid lines were obtained by a fit of these
data and those obtained in a replicate experiment to a single ideal
species model, which yielded MW =97,2106810; the residuals are
shown above. (B) Circular dichroism analysis of all hHOGA variants
within this study. Buffer conditions: 0.2 mg ml
21 HOGA variant, 20 mM
HEPES pH 7.5, 100 mM NaCl, 25uC. Data are presented as molar
ellipticity vs. wavelength.
doi:10.1371/journal.pone.0026021.g004
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parameters quite similar to the S77T variant.
Assessment of residues involved in substrate specificity
In an effort to understand how hHOGA binds HOG and the
apparent lack of stereospecificity for the 4-hydroxyl moiety, we
generated a model for how each stereoisomer of the Lys196-HOG
Schiff base intermediate could bind within the active site
(Figure 7B). The (R)- and (S)-stereoisomers of HOG were
generated with the Dundee PRODRG2 server and energy
minimized [36]. The pyruvate portion of each HOG molecule
was superimposed onto the pyruvate molecule of the crystal
structure (Figure 6). Only minor rotational adjustments about the
C3-C4 and C4-C5 bonds (Figure 1) were necessary to optimize the
hydrogen-bonding distances and geometry for interactions with
the side chain of Asn78, Ser198, and the backbone carbonyl group
of Gly222. It is important to note that Asn78 and Ser198 of
hHOGA are substituted within E. coli DHDPS active site to Thr45
and Ala163, respectively, (Figure 7A). The resulting models
support that hHOGA can readily bind both HOG stereoisomers
and highlights the potential importance of Asn78, Ser198, and
Gly222 for the binding of HOG.
Site-directed mutants of Asn78 and Ser198 were evaluated to
test the importance of these side chains to the hHOGA reaction.
Circular dichroism spectra of all variants were similar to the WT
enzyme (Figure 4B). While replacing the side chain of Asn78 with
a methyl group (N78A) caused no change in turnover (kcat)
(Table 2), a 6-fold increase in the KM yielded a 4.8-fold reduction
in kcat/KM relative to the WT enzyme. Interestingly, the N78T
variant, which mimics the DHDPS enzymes, exhibited a 1.5-fold
decrease in kcat, but retained a WT-like KM value. Asn78 was also
mutated to Gln to test whether extending the side chain by one
carbon atom would affect catalysis. This mutation caused a drastic
loss in catalytic efficiency (kcat/KM), primarily due to the 25-fold
Table 1. Crystallographic data and refinement statistics.
Crystal EMTSNhHOGA Native hHOGA PyruvateNhHOGA
Processing
Spacegroup P6422 P6422 P6422
Unit Cell Parameters
a, b, c (A ˚) 141.9, 141.9, 107.6 142.1, 142.1, 108.1 141.2, 141.2, 108.4
a, b, c (u) 90, 90, 120 90, 90, 120 90, 90, 120
Wavelength (A ˚) 1.54 1.50 1.54
Resolution
a (A ˚) 29.60–2.10 (2.18–2.10) 59.38–2.50 (2.59–2.50) 35.17–1.97 (2.04–1.97)
Rmerge (%) 7.4 (33.4) 6.9 (26.7) 5.0 (34.0)
Rmeas (%) 7.5 (34.4) 7.0 (27.0) 5.2 (35.4)
,I/sI. 25.2 (6.1) 28.3 (11.4) 20.8 (5.7)
Completeness (%) 99.9 (98.1) 100 (100) 99.9 (100)
Redundancy 36.7 (16.9) 41.3 (42.0) 13.8 (12.3)
Wilson B (A ˚2) 31.1 42.4 29.9
FOM
Initial 0.51
After density modification 0.70
Refinement
Rwork/Rfree (%) 28.0/29.5
b 21.2/24.6 19.6/21.6
No. of reflections (work/free) 21,644/1,170 43,028/2,287
No. atoms
Protein 2,232 2,256
Ligands 24 30
Water 47 211
RMSD Bond Lengths (A ˚) 0.012 0.014
RMSD Bond Angles (u) 1.433 1.428
Average B-factor (A ˚2)
Protein 42.3 28.9
Ligands 52.8 39.9
Solvent 41.4 39.7
Ramachandran analysis
Favored regions 96.9% 98.0%
Allowed regions 3.1% 2.0%
aNumbers in parentheses are for the highest resolution shell. The same full resolution range was used for refinement.
bThese values were obtained after solvent flattening and one round of CNS refinement.
doi:10.1371/journal.pone.0026021.t001
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Ser198 of hHOGA in DHDPS is an Ala. This side chain
difference makes sense, as the DHDPS substrates do not contain a
hydroxyl group comparable to the 4-hydroxyl group of HOG.
Mutating Ser198 to Ala caused a 2.5-fold decrease in kcat and a
4.2-fold increase in KM, resulting in a 10-fold decrease in kcat/KM
compared to WT hHOGA. The S198T variant, which should be
able to interact with the 4-hydroxyl group of HOG, exhibited a 7-
fold increase in KM, but a kcat value comparable to WT.
Figure 6. Active site structure of hHOGA. (A) Pyruvate-Schiff base
complex. The 1.97 A ˚ resolution, 2Fo-Fc electron density map is shown in
gray and contoured to 1.5 s. The pyruvate molecule is highlighted by a
green Fo-Fc omit map contoured to 6.4 s. Atom colors are as follows:
blue, nitrogen; light-orange, carbon atoms for hHOGA; green, carbon
atoms for pyruvate; red, oxygen. (B) Comparison to the unliganded
active site. Coloring for pyruvate bound hHOGA is the same as in (A).
White coloring is used for unbound hHOGA. Tyr1409 from the adjacent
monomer are colored in a darker shade of orange and gray,
respectively. A water molecule adjacent to Lys196 is depicted as a
red sphere in the unbound hHOGA structure.
doi:10.1371/journal.pone.0026021.g006
Figure 5. Structure of human HOGA. (A) Homo-tetrameric
organization of hHOGA. The tetramer consists of a dimer of dimers
(orange and gray). (B) The hHOGA monomer. Two orthogonal views
illustrate the overall architecture, TIM barrel fold, and C-terminal helical
bundle. Coloring is as follows: gray, a-helices; orange, b-strands; light-
orange, loop regions.
doi:10.1371/journal.pone.0026021.g005
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The catabolism of 4-Hyp derived from endogenous and dietary
sources contributes to the levels of glyoxylate, glycolate, and
glycine (Figure 1) within liver and kidney cells [11,19]. The
synthesis and breakdown of these metabolites is altered in PH
patients and can lead to conversion of glyoxylate to oxalate and
the subsequent formation of kidney stones and in extreme cases
kidney failure [4]. Therefore, the pharmacologic or genetic
manipulation of 4-Hyp catabolism and glyoxylate formation holds
promise for these patients, but the human enzymes have not been
biochemically characterized. Historically, the 4-Hyp catabolic
pathway has been delineated primarily from the analysis of
mitochondrial extracts from the kidneys and livers of rats and cows
[8,14–18]. In this study, we purified HOGA from bovine kidney
mitochondria and used mass spectrometry to determine its protein
sequence and corresponding gene sequence (Figure 2). With this
information in hand, the gene for the human HOGA protein,
HOGA1, was identified, cloned into an E. coli expression vector,
and the protein purified to homogeneity. Recombinant hHOGA
readily cleaves HOG yielding two products, glyoxylate and
pyruvate (Figure 3 and Figure S6), thus demonstrating for the
first time a direct gene-protein-activity correspondence for
hHOGA.
From a chemical perspective, the reaction catalyzed by
hHOGA is reminiscent of KDPGA from E. coli (Figure 3) and
related bacterial enzymes that function in a trimeric assembly of
monomers exhibiting the (b/a)8-barrel fold (Figure S1A and B)
[23–25]. These enzymes cleave similar substrates, utilize a Lys-
Schiff base intermediate, and produce pyruvate as one of the
products. Therefore, we were surprised when sequence analyses
showed that hHOGA is actually related to the bacterial DHDPS
enzymes (Figure 2B) involved in lysine biosynthesis [26–29]. The
latter enzymes also utilize a conserved Lys residue and function as
a tetrameric, (b/a)8 assembly (Figure 2 and Figure S1C and D).
Our analysis of recombinant hHOGA by sedimentation
equilibrium ultracentrifugation, size-exclusion chromatography,
and dynamic light scattering (Figures 4A, S2 and S4) suggests that
hHOGA may exhibit unusual solution behavior, with the data
supporting trimeric, tetrameric, and potentially even higher-order
assemblies. Fits of the ultracentrifugation data to monomer-dimer-
tetramer and dimer-tetramer equilibria support the latter (Figure
S3). A range of oligomeric states (72–144 kDa; i.e., dimer to
tetramer) have also been observed for the rat and bovine enzymes,
although the bovine enzyme was found to be a tetramer
[14,15,18,22]. A similar situation occurred with the structurally
and functionally-related N-acetylneuraminate lyase enzymes that
were first thought to be trimers, but were later found to be
tetramers once the crystal structure was determined [37,38].
Moreover, it is possible that hHOGA may exist as a mixture of
dimers and tetramers (i.e., dimer of dimers, Figure 5A) in solution
at low concentration, an observation found for some DHDPS
variants [34,39]. Altogether, these observations and the new
crystal structures of hHOGA (Figures 5 and 6) support that
HOGA is most likely functional as a tetramer.
The connection between hHOGA and the DHDPS enzymes is
quite intriguing, as the favored reaction directions are opposite
(Figure 3). DHDPS enzymes preferentially perform a condensa-
tion reaction [26–29]. In contrast, the equilibrium constant for the
cleavage reaction for bovine and rat HOGA, determined using
14C-labeled substrates, ranges from 9.0–11.9 [18,40]. These
hHOGA homologs, however, can perform a condensation
reaction between glyoxylate and pyruvate and several pyruvate
analogs, although the reaction rates are 1,000–10,000-fold slower
[14,41,42]. Nonetheless, it is possible that hHOGA could be
modified to be useful for carbon-carbon bond formation and the
synthesis of complex molecules, as has been observed for the native
and various engineered forms of KDPGA and other bacterial
enzymes [23,43–45]. One significant difference for HOGA,
however, is that it is not stereospecific for either the R-o rS-
forms of HOG [15,18,22]. It is of interest to note that the
tetrameric 2-keto-3-deoxygluconate aldolases from Sulfolobus
solfataricus and Thermoproteus tenax are additional examples of
distantly-related, DHDPS-like enzymes that can perform a
cleavage reaction similar to HOGA [46,47].
hHOGA shares several active site residues with E. coli DHDPS
(Figure 2B). Tyr107, Tyr133, and Lys161 of E. coli DHDPS
correspond to Tyr140, Tyr168, and Lys196 of hHOGA
(Figure 7A). Tyr107 and Tyr140 protrude into the active site of
an adjacent monomer within the tetramer. Mutational analyses of
E. coli DHDPS support that Tyr107, Tyr133, and Thr44, a residue
unique to DHDPS discussed in more detail below, facilitate
catalysis by functioning as a proton shuttle between the active site
and solvent [35]. The loss in activity for the Y168F and Y133F
Figure 7. Structural comparisons between hHOGA and E. coli
DHDPS. (A) Superposition of hHOGA and E. coli DHDPS (PDB ID: 3DUO)
pyruvate-bound active sites (RMSD =0.19 A ˚ for Ca atoms) [28]. hHOGA
coloring is the same as in Fig. 6. DHDPS carbon atoms are colored in
pale cyan and cyan (adjacent subunit). Carbon atoms for pyruvate
bound to DHDPS are colored gray. Hydrogen bonds are shown using
dashed lines for hHOGA (gray) and DHDPS (blue). Amino acid residues
for the two enzymes are indicated in the following order: hHOGA/
DHDPS. (B) Model of the HOGNhHOGA complex. HOG carbon atoms and
putative hydrogen bonds to hHOGA are colored yellow (R-form) and
cyan (S-form).
doi:10.1371/journal.pone.0026021.g007
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with the role of this residue to function as a general acid/base in
the proton shuttle. The 12-fold loss in activity for the Y107F E. coli
DHDPS variant, however, contrasts with the wild-type activity of
the equivalent Y140F hHOGA mutant (Figure S6), supporting
that this residue does not play as essential a role as in the DHDPS
enzymes [35]. Lys161 forms a Schiff base with pyruvate, and the
mutation of Lys161 to Arg and Ala in this DHDPS resulted in a
300–800-fold loss in activity [48]. The Schiff base intermediate
observed within the hHOGA crystal structure (Figure 6) and the
inactivity of the K196A variant (Table 2) support that this residue
plays the same functional role in hHOGA catalysis.
The crystal structure of hHOGA in complex with pyruvate
(Figures 6A and 7A) illustrates how the highly conserved G-X-X-
G-E motif fulfills the same carboxylate-binding role via two
backbone amide nitrogen atoms. This motif contains Thr44-
Thr45 in the X-X positions for E. coli DHDPS, while hHOGA
contains Ser77-Asn78. Importantly, the side chain of Thr44/
Ser77 interacts with Tyr133/Tyr168 (Figure 7A). The modulation
of all kinetic parameters for site-directed variants of these residues
for both enzymes is consistent with their role in substrate binding
and catalysis. For example, it was originally thought that mutating
Ser77 to Thr would maintain a WT level of hHOGA activity
because of the conservation of the hydroxyl functional group. The
S77T variant, however, caused a significant decrease in kcat and
kcat/KM values (Table 2). Similar findings have been observed for
the DHDPS enzyme where the Thr was mutated to Ser (kcat
reduced 12-fold) [49]. Mutation of Ser77 to Ala and Val also
exhibited reduced kcat and kcat/KM values compared to WT
hHOGA, further supporting the importance of this hydroxyl
group in the proposed proton relay. As noted above, however,
hHOGA differs from E. coli DHDPS in that Tyr140 from the
adjacent monomer appears not to be necessary for the shuttling of
protons.
With the binding mode of the pyruvate-Schiff base intermediate
in hand, we sought to model the interaction of the HOG-based
imine intermediate in order to identify additional residues that
could influence substrate binding and catalysis. Both the S- and R-
forms of HOG were readily docked into the active site (Figure 7B).
Several putative interactions were readily identified: the side chain
of Asn78 with the terminal carboxyl group at the 5-position of
HOG (Figure 1), the side chain of Ser198 with the 4-hydroxyl
group, and a bifurcated interaction between the backbone
carbonyl oxygen atom of Gly222 and the 4-hydroxyl group and
one of the terminal carboxyl oxygen atoms of HOG. Asn78 of
hHOGA was mutated to Ala, Thr, and Gln to evaluate its
potential role. Interestingly, the Ala variant exhibited a similar kcat
value but a 6-fold increase in KM compared to WT hHOGA
(Table 2). The Thr variant, which mimics Thr44 of E. coli
DHDPS, exhibited a significant decrease in kcat, but a WT-like KM
value. Extension of the side chain to Gln, however, caused a
dramatic loss kcat/KM due to a 25-fold increase in the KM value for
HOG. These results are consistent with severely compromised
activity of comparable DHDPS variants [35,50], further support-
ing an important role for Asn78 in substrate binding and catalysis.
The presence of Ser198 and its putative interaction with the 4-
hydroxyl group of HOG are unique to HOGA enzymes. E. coli
DHDPS has an Ala163 at the equivalent position (Figure 7A). The
S198T variant, which should be able to interact with the 4-
hydroxyl group of HOG, exhibited a 7-fold increase in KM, but a
kcat value (Table 2) comparable to the WT enzyme. The Ala
variant exhibited decreased catalytic activity, increased KM values,
and decreased overall efficiency. These data, the conservation of
Ser198 and Asn78 for the HOGA enzymes, and the lack of these
residues in the DHDPS enzymes are also consistent with the
differences in the substrate size and chemical structure beyond the
core pyruvate molecule. Further support for this notion comes
from the mutational analysis of Arg138 of E. coli DHDPS, which
has been shown to be important for binding of the second
substrate, (S)-aspartate-b-semialdehyde, near Tyr133 and Tyr107
and may also function to stabilize the proton relay [50]. Arg138 is
substituted by Asn173 in hHOGA. Altogether, these data support
the unique interactions of Asn78 and Ser198 with HOG.
Based on the new structural and kinetic data presented
(Figures 5–6 and Table 2), as well as the comparisons to the
well-studied structures (Figure 7) and mechanisms of the DHDPS
and N-acetylneuraminate lyase enzymes, a classical, type 1
aldolase reaction mechanism for hHOGA can be proposed
(Figure 8). HOG binds within the hHOGA active site so that
the 2-oxo carbonyl group is adjacent to Lys196, the adjacent
carboxylate binds to the backbone amide nitrogen atoms of Ser77-
Asn78, the 4-hydroxyl group interacts with the unique residue
Ser198, and the distal carboxylate interacts with the backbone
carbonyl of Gly222 and the side chain of Asn78. The e-amino
Table 2. Kinetic parameters.
kcat (sec
-1) KM (mM) kcat/KM (M
-1 sec
-1) 610
3 Relative kcat Relative kcat/KM
WT 6.160.1 11615 5 5 650 1.00 1.00
S77A 2.560.1 84653 0 62 0.41 0.05
S77T 0.860.1 58681 4 62 0.13 0.02
S77V 1.260.1 82671 5 61 0.20 0.02
N78A 7.660.1 66641 1 5 67 1.25 0.20
N78T 4.060.1 16612 5 0 616 0.66 0.45
N78Q 6.260.1 281614 2261 1.02 0.04
Y140F 5.260.1 8616 5 0 681 0.85 1.22
Y168F –
a –– ––
K196A ––– ––
S198A 2.460.1 44625 5 63 0.39 0.09
S198T 7.860.1 77651 0 1 67 1.28 0.18
aNo activity measured with the addition of 1.5 mM enzyme to the reaction containing 450 mM substrate.
doi:10.1371/journal.pone.0026021.t002
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nucleophilic attack (step a) on the 2-oxo group of HOG to form a
zwitterionic intermediate that readily converts to a carbinolamine.
The addition of a proton from the proton relay involving residues
Tyr168 and Ser77 (step b) leads to dehydration (step c) and
formation of the Schiff base with Lys196. This intermediate
rearranges (step d) to release a proton and the first product of the
reaction, glyoxylate. The resulting enamine can tautomerize (step
e) to form the pyruvate-based imine. The addition of a water
molecule, loss of a proton, and collapse of the resulting
carbinolamine (steps f–h) ultimately leads to the release of pyruvate
so that the catalytic cycle can begin again.
During the course of this study, 15 previously unclassified PH
patients were shown to exhibit six mutations in a putative DHDPS-
like protein [12]. Further analyses have identified four additional
mutationsin PHpatients [13].A series ofassumptions weremade to
suggest that the DHDPS-like protein performs the same function as
hHOGA. They proposed that the enzymes were the same based on
the bovine enzyme being involved in glyoxylate metabolism,
performing a lyase reaction, and being localized primarily in the
mitochondria of liver and kidney [12]. However, no experimental
data confirming any of these attributes for the human enzyme was
available at that time. A direct link between the rat and bovine
HOGA activity to the DHDPSL gene was also not possible, as the
sequences for the neither the gene nor protein were determined.
Nonetheless, it was proposed that these patients be reclassified as
PH3. The experimental data presented herein definitively shows
that hHOGA is indeed the enzyme responsible for the cleavage of
HOG to glyoxylate within the 4-Hyp degradation pathway.
Belostotsky et al. have also hypothesized that the mutation of
HOGA in PH3 patients results in an increase in glyoxylate and
oxalate production, despite having functional AGT and GR
proteins (Figure 1) that should be able to handle the level of
glyoxylate produced from 4-Hyp [12]. An equally attractive
alternative hypothesis for why mutations in HOGA cause PH3 is
that the activity of HOGA is partially or completely attenuated. In
this scenario, the HOG, and perhaps the preceding metabolites,
may increase in concentration and be ultimately converted to
glyoxylate and pyruvate by an enzyme(s) that remains to be
identified. An imbalanced metabolism may result in much more of
the glyoxylate being converted to oxalate rather than glycolate, as
occurs normally. A mapping of the nine exonic mutations
identified to date onto the hHOGA structure (Figure 9) suggests
some potential reasons for a loss in catalytic activity.
Four of the hHOGA variants can be categorized as potential
active site disrupting mutants. The mutation of Pro190 to Leu,
located in the turn connecting a-helix 5 to b-strand 5 where the
essential catalytic residue Lys196 and substrate-positioning residue
Ser198 reside (Figure 9A, highlighted in magenta), most likely
disrupts the correct positioning of these key functional residues.
The R70P mutation is located on the underside surface of the
molecule upstream from the G76-X-X-G-E80 pyruvate-binding
motif (Figure 9A, blue coil). The introduction of a Pro at this
position could affect the register of Ser77 and Asn78 and therefore
alter substrate binding and catalysis (Figures 7B and 8). The
G287V and R303C variants may also disrupt the positioning of
the G-X-X-G-E motif. Gly287 is located in a turn at the start of a-
helix 10 and just two residues away from Lys289, which is involved
Figure 8. Proposed mechanism for hHOGA catalysis. The enzyme residues are highlighted in bold. See text for details.
doi:10.1371/journal.pone.0026021.g008
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a salt bridge, but with another conserved residue, Glu88,
downstream (not shown). The consequences of the R97C and
T280I mutations are not obvious as they are not near the active
site or the interface between the monomers within the tetramer.
The remaining mutations, R255X,C257G and DE315, aremore
distant from the hHOGA active site and most likely affect the
overall folding and equilibrium between dimer and tetramer.
R255X is a nonsense mutation that would truncate the entire C-
terminal, three-helical bundle, a key feature of the loose dimer-
dimer interface (Figure 5A and 9B). The C257G variant is located
nearby and may also affect the structural transition between the
TIM barrel and the three-helical bundle. The DE315 variant results
inthedeletionofone GluresidueinatripletGlumotifpresentinthe
C-terminal helix. While this variant maintains the protein coding
register, it could potentially alter the entire structure of this helix,
also resulting in the disruption of the dimer-dimer interface. Further
support for tetramer destabilization in these PH3 variants comes
from the analysis of E. coli DHDPS variants. The variants were
engineered to disrupt the tight monomer-monomer interaction
involving Tyr107 and the loose dimer-dimer interface [32–34].
Mutation of Tyr107 to Trp resulted in a mixture of monomer and
tetramer in solution and a loss in activity and thermal stability. The
addition of the L197D mutation, a residue at the dimer-dimer
interface, completely shifted the protein to the monomer, led to a
further loss in activity, and resulted in an increased propensity for
aggregation.Removalofthe entireC-terminal,3-helical bundlealso
compromised activity and quaternary structure.
Figure 9. Location of mutations identified within hHOGA of PH3 patients. (A) Close-up view of one hHOGA monomer. The cartoon of the
protein has been made partially transparent so that the PH3 mutations (spheres; see legend) are highlighted. The G-X-X-G-E motif is illustrated as a
blue cartoon tube. The portion of the protein structure leading from the P190L variant to the active site Lys196-pyruvate adduct (stick rendering) is
shown in magenta. (B) Three orthogonal views of the hHOGA tetramer illustrate the proximity of the mutations to the monomer-monomer (red
dashed line) and dimer-dimer interfaces (blue dashed line). The red and blue squares indicate when an axis is projecting out toward the viewer.
doi:10.1371/journal.pone.0026021.g009
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spectrometry of the bovine enzyme from kidney mitochondria.
The enzyme readily cleaves HOG and exhibits unusual solution
properties, but most likely functions in solution as a tetramer due
to its sequence and structural conservation with bacterial DHDPS
enzymes. The crystal structure of the enzyme in complex with
pyruvate has enabled the modeling of the HOG complex and led
to the identification of key active site residues. Kinetic analyses
confirm the necessity for Tyr168 and Lys196 in catalysis.
Moreover, key roles for Ser77, Asn78 and Ser198 have been
ascribed. The location of mutations found in PH3 patients suggest
that some mutations directly affect the active site architecture
while others may affect the oligomeric state. As a result, this study
lays the foundation on which to assess the effect of HOGA
mutations observed within PH3 patients on enzyme activity,
protein folding, and subcellular targeting, all potential functional
consequences previously observed in PH1 and PH2 patients
[51,52]. Experiments to evaluate these possible scenarios are
currently in progress.
Materials and Methods
Synthesis of 4-hydroxy-2-oxoglutarate
The substrate for HOGA was synthesized via a base-catalyzed
aldol condensation between oxaloacetate and glyoxylate [14,20].
Briefly, a 25 mL 0.1 M KOH solution containing 0.92 g
glyoxylate and 1.32 g oxaloacetate (1:1 molar ratio) was adjusted
to pH 12 using 10 M KOH and allowed to sit overnight. The
solution became light yellow during this process and was tested
using a phenylhydrazine assay to confirm that all of the glyoxylate
had been consumed [21]. The pH was gradually decreased to
,pH 5.5 using concentrated HCl; the solution bubbled vigorously
during this decarboxylation step. The solution was quickly
concentrated to ,10 mL using a rotary evaporator set to 40uC;
a higher temperature leads to degradation of HOG. HOG was
then passed over a formate-form AG 1X8 column (BioRad, 200–
400 mesh) equilibrated with water in order to remove chloride
ions. The resulting solution was concentrated and passed over a
H
+-form AG 50W-X8 column (BioRad, 200–400 mesh) to remove
potassium ions. The eluent was diluted with water and
concentrated by roto-evaporation several times to remove formate.
The final solution was concentrated to ,5–6 mL, aliquoted, and
stored at 220uC. A fresh aliquot was thawed for each experiment
and kept on ice. The concentration of the HOG stock was
determined by monitoring the total change in absorbance at
340 nm with a lactate dehydrogenase-coupled assay described in
detail below.
Purification of HOGA from bovine kidney
HOGA was purified from the cortex region of three freshly
dissected bovine kidneys (88 g; Mitchells Meat Processing
Company, Walnut Cove, NC) using a procedure adapted from
Dekker et al. [15]. The tissue was resuspended in 900 mL of buffer
A (225 mM mannitol, 75 mM sucrose, 5 mM MOPS pH 7.0,
0.1 mM EDTA, and four EDTA-free protease inhibitor tablets
(Roche Diagnostics). The tissue was homogenized using a
Brinkmann homogenizer (power setting 4.5) with 3 bursts,
30 sec each. Phenylmethylsulfonyl fluoride and benzamidine were
added to a final concentration of 1 mM before centrifugation at
2,000 rpm for 20 min. The supernatant was decanted and the
remaining liquid and pellet were then centrifuged at 8,500 rpm
(JA-20 rotor) for 10 min. The pellets were washed with buffer A
three more times and then centrifuged at 18,000 rpm for 20 min,
yielding ,12 g of purified mitochondria that were stored at
280uC. Six grams of mitochondria in buffer A were heated to
70uC, and the resulting precipitate was removed by centrifugation
at 18,000 rpm for 20 min. The supernatant was processed using
AmSO4 fractionation (20–60% cuts in 10% increments) in buffer
B (50 mM TRIS pH 7.8 and 2.5 mM dithiothreitol (DTT)). The
phenylhydrazine assay was used to identify that the 30–40% (w/v)
AmSO4 fractions contained HOGA activity, i.e. formed glyoxylate
from HOG [21]. These sample pools were dialyzed into buffer B
and fractionated using a DEAE Macro-Prep column (Bio-Rad)
and a 0–500 mM NaCl gradient over 900 mL. Those fractions
containing the highest HOGA activity were pooled, concentrated
to 5 ml using a VivaSpin20 device with a 10 kDa cutoff, and
loaded onto a Superdex 200 size-exclusion column (GE Health-
care) equilibrated with 50 mM TRIS pH 7.8, 100 mM NaCl, and
2.5 mM DTT. HOGA was concentrated to 2.1 mg ml
21,
aliquoted, frozen with liquid N2, and stored at 280uC.
Identification of bovine and human HOGA genes by mass
spectrometry
Bovine HOGA was submitted to the W. M. Keck Foundation
Biotechnology Resource Laboratory (New Haven, CT) for
analysis. In summary, the protein was denatured by the addition
of 8 M urea/0.4 M NH4HCO3. The Cys residues were blocked
by the addition of iodoacetamide. Trypsin was added at a 1:15 wt/
wt ratio (Promega V5111) and the volume was increased to 80 mL
using H2O. The sample was digested at 37uC for 18 hr. LC-MS/
MS data were collected on a Waters Q-Tof Ultima mass
spectrometer and analyzed by MASCOT (Matrix Science Ltd.).
Recombinant expression and purification of human
HOGA variants
The human HOGA gene (HOGA1) was subcloned into the
pET151/D-TOPO vector (Invitrogen) so that the mitochondrial
targeting sequence was removed (i.e., the protein started at residue
26). In addition, this construct contained an N-terminal His-tag
and an engineered, intervening PreScission Protease recognition
site (GE Healthcare) to facilitate removal of the affinity tag. The
S77A, S77T, S77V, N78A, N78T, N78Q, Y140F, Y168F,
K196A, S198A, and S198T mutants of hHOGA were made
using the QuikChange site-directed mutagenesis procedure
(Stratagene).
The wild-type (WT) and the Y140F, Y168F, and K196A
hHOGA variants were overexpressed in 6 L cultures of
BL21*(DE3) Escherichia coli at 37uC. The culture was induced by
the addition of 0.1 mM isopropyl-b-D-thio-galactoside (IPTG)
once the OD600 reached 0.6–0.8, and the temperature decreased
to 16uC overnight. The cells were resuspended in 100 mL of
buffer C (50 mM HEPES pH 7.9, 500 mM KCl, 0.1% Triton X-
100, 10% glycerol, 0.5 mM imidazole, 1 mM PMSF and
benzamidine), lysed using an Avestin Emulsiflex-C5 cell homog-
enizer, and loaded onto a nickel nitrilotriacetic acid affinity
column (Qiagen). The column was sequentially washed with
several column volumes of buffer C and buffer C that did not
contain the Triton X-100, glycerol, and protease inhibitors.
HOGA was eluted with a 5–250 mM imidazole gradient. The
desired fractions, as determined by SDS-PAGE analysis, were
pooled, dialyzed into 20 mM HEPES pH 8.5, and fractionated on
a Q-Sepharose HP column (GE Healthcare) with a 0–0.5 M NaCl
gradient over 300 mL. The fractions containing HOGA were
further purified via passage over a Superdex 200 size-exclusion
column equilibrated with 20 mM HEPES pH 7.5, 100 mM NaCl.
The protein was readily concentrated to 10–20 mg mL
-1,
aliquoted, frozen on liquid N2, and stored at 280uC. For
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treated with PreScission Protease (50:1 ratio, 15 mM DTT; GE
Healthcare) overnight at 4uC prior to the anion exchange column
step. Removal of the His-tag was confirmed by mass spectrometry.
The molecular masses of the hHOGA with and without the His-tag
are36,136Daand 33,097Da,respectively.TheHis-tag free protein
does contain three additional N-terminal residues (GPH) that were
originally part of the PreScission Protease recognition site.
In an effort to overcome low solubility and poor overall yields,
some hHOGA variants (S77A, S77T, S77V, N78A, N78T, N78Q,
S198A, and S198T) were subcloned into the pMal expression
vector (New England BioLabs). In this process, an intervening
PreScission Protease cleavage sequence was engineered. The
expression conditions and purification scheme were modified as
follows. The BL21-Gold (DE3) E. coli cells were induced with
0.3 mM IPTG. The cells were resuspended with 20 mM TRIS
pH 7.5, 200 mM NaCl and lysed. The cleared cell lysate was first
passed over an amylose column (New England Biolabs) pre-
equilibrated with 20 mM TRIS pH 7.5, 200 mM NaCl. Bound
MBP-hHOGA was eluted off the column via the addition of
10 mM maltose. Overnight dialysis exchanged the buffer to
20 mM TRIS pH 8.5, 0.5 mM dithiothreitol (DTT), and 0.1 mM
EDTA. PreScission Protease (50:1) was added to cleave MBP from
HOGA during dialysis at 4uC. Removal of the MBP-tag was
confirmed by mass spectrometry. A Q-Sepharose HP column was
used to separate cleaved MBP from hHOGA. Glutathione S-
Sepharose was also used to remove any remaining PreScission
Protease. The remaining size-exclusion, concentration, and
storage parameters were the same as described as above. Typical
yields for all proteins were 10–30 mg from a 6 L culture.
The global folding of each hHOGA variant was evaluated by
triplicate circular dichroism (CD) spectra that were averaged from
200–250 nm at 25uC, using a cuvette with a 0.05 cm path length
on a Jasco 720 spectrometer. The proteins were diluted to 0.2 mg
mL
21 in 20 mM HEPES pH 7.5, 100 mM NaCl. Data are
presented as molar ellipticity vs. wavelength.
Measurement of HOGA activity
A standard lactate dehydrogenase (LDH) coupled-enzyme assay
was used to assess the activity of hHOGA by monitoring the
production of pyruvate from the cleavage of HOG. The decrease
in NADH absorbance at 340 nm was continuously monitored
using a Cary50 spectrophotometer. The reaction rates were
converted to M s
21 using the extinction coefficient for NADH
(e=6220 M
21 cm
21). The 200 mL reactions contained 10–
100 nM hHOGA, 200 mM NADH, 100 mM TRIS pH 8.5,
200 mU LDH (Sigma; Rabbit muscle Type 2), and 4.7–400 mM
HOG. The reactions were run at 37uC in triplicate and repeated
on several different days with fresh aliquots of hHOGA and HOG.
The kcat, KM, and kcat/KM values for HOG were determined
utilizing nonlinear regression analysis in the enzyme kinetics
module of SigmaPlot 11.0 (Systat Software, San Jose, CA).
Oligomeric state analyses
Three different techniques were used to evaluate the oligomeric
state of hHOGA. First, as a part of the purification process,
hHOGA was passed over a calibrated Superdex 200 size-exclusion
column. The calibrants used were blue dextran (2,000 kDa),
aldolase (158 kDa), bovine serum albumin (67 kDa), ovalbumin (43
kDa), and ribonuclease A (12.7 kDa) (GE Healthcare). Second,
sedimentation equilibrium analytical ultracentrifugation data for
three protein concentrations and two rotor speeds (7,500 and
10,500 g) werecollectedusinga Beckman OptimaXL-Ainstrument
using 12 mm double sector cells with quartz windows and an An60-
Ti analytical rotor. The analyses were performed on both the His-
tag- and MBP-free versions of hHOGA diluted in 20 mM HEPES
pH 7.5, 100 mM NaCl. The protein concentrations for these
experiments were as follows: experiment #1, 0.43, 0.82, 1.25 mg
ml
21; experiment #2, 0.46, 0.78, 1.14 mg ml
21. Data were
analyzed globally using the HETEROANALYSIS package (Ver-
sion 1.1.28, J.W.Cole andJ.W.Lary,AnalyticalUltracentrifugation
Facility, Biotechnology/Bioservices Center, University of Connecti-
cut, Storrs, CT). The partial specific volume of 0.7396 cm
3 g
21
(calculated from amino acid composition), solvent density of
1.0039 g cm
23 (measured with a Mettler DA310 Density/Specific
Gravity Meter), and a single ideal species model were used to
determine the weight-average molecular weight for each prepara-
tion. The data were also fit to monomer-dimer-tetramer and dimer-
tetramer equilibria using HETEROANALYSIS and SEDPHAT
(Version 8.2) [30]. Third, dynamic light scattering data were
collected on 0.25–25 mg mL
21 hHOGA solutions in the same
buffer above using a Malvern Zetasizer NanoS instrument.
Human HOGA crystallization
Crystals of HOGA were obtained by the vapor diffusion
method. Equal volumes of protein (12 mg mL
21 in 20 mM
HEPES pH 7.5, 100 mM NaCl) and well solution (18% PEG
3350, 200 mM KSCN, 100 mM Bis-tris propane pH 7.5, 15 mM
TCEP, 25% ethylene glycol) were mixed and incubated at 20uC
for 3–7 days as hanging drops. For the pyruvate bound hHOGA
crystals, 10 mM sodium pyruvate was added to the protein
solution prior to setting up the crystal trays. For the ethylmercur-
iothiosalycilate (EMTS)-derivatized hHOGA crystals, 500 mM
EMTS was incubated with hHOGA at 4uC overnight. Excess
EMTS was removed via a Bio-Rad P-6 desalting column before
setting up crystallization experiments.
Data collection and structure determination
A single-wavelength anomalous dispersion (SAD) dataset was
collected using an in-house Rigaku/MSC MicroMax-007 gener-
ator with a Saturn-92 CCD detector on EMTS-containing crystals
of hHOGA. X-ray diffraction data for the apo hHOGA crystals
were collected on beamline X25 (l=1.5 A ˚) at the National
Synchrotron Light Source (Upton, NY) using an ADSC
Quantum-4 CCD detector. For the pyruvate bound hHOGA
crystals, data were collected in-house using a Rigaku/MSC RU-
H3R generator with an R-Axis IV image plate detector. All
datasets were processed with d*Trek (Rigaku/MSC, The
Woodlands, TX) [53]. All crystals exhibited P6422 symmetry
(a=b=141 A ˚, c=108 A ˚) with one molecule in the asymmetric
unit. PHENIX AutoSol was used to detect the anomalous signal
from the heavy atom dataset and generate initial electron-density
maps [54]. A total of 23 EMTS sites were found with occupancies
ranging from 0.07–1.0, three of which were used for phase
determination. An initial FOM value of 0.51 was obtained and
improved to 0.71 following density modification. The AutoBuild
routine within PHENIX was able to build 97% of the structure.
After several rounds of refinement using CNS, the heavy-atom
based model was used as a molecular replacement search model
within PHASER for the uncomplexed and pyruvate bound
hHOGA datasets [31]. All models were initially refined with
CNS using alternating cycles of simulated-annealing, positional,
and B-factor refinement [55]. Model building was performed with
COOT [56]. Water molecules were identified with a Fo–Fc map
contoured at 3 s and added with COOT. Several ethylene glycol
molecules were also added. The final cycles of refinement were
performed with REFMAC5 [57]. The structures were validated
using the MolProbity server, which reported 96.9–98% of the
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data collection and refinement statistics are summarized in
Table 1. All structural figures were generated with PyMOL (The
PyMOL Molecular Graphics System, Version 1.3, Schro ¨dinger,
LLC.). The coordinates and structure factors for the apoenzyme
(PDB ID: 3S5N) and pyruvate-Schiff base complex (PDB ID:
3S5O) have been deposited to the Protein Data Bank (PDB).
Supporting Information
Figure S1 Quaternary structure and pyruvate complexes
of representative KDPGA and DHDPS enzymes. (A) Trimeric
organization of T. maritima KDPG aldolase (PDB ID: 1WA3) [24]. (B)
Pyruvate complex of T. maritima KDPGA. The pyruvate molecule
(cyan) is covalently attached as a Schiff base to Lys129 and interacts
with Arg17. A hydrogen-bonding network includes intervening water
molecules, Glu40, Lys129, and Thr156. The adjacent monomer
contributes two amino acids (Ala1439 and Pro1479) near this region
and binds a sulfate ion, most likely mimicking the phosphate binding
site for these enzymes. (C) Tetrameric organization of E. coli DHDPS
(PDB ID: 3DU0) [28]. The tetramer consists of a dimer of dimers. (D)
Active site of E. coli DHDPS. The pyruvate molecule (cyan) is
covalently attached as a Schiff base to Lys161 (green) and interacts with
Thr45. A hydrogen-bonding network is formed between Thr44,
Tyr133, and Tyr1079 from the adjacent monomer (gray).
(TIF)
Figure S2 Size exclusion chromatography analysis of
hHOGA molecular weight. Protein standards (blue diamonds)
were used to calibrate a Superdex 200 gel filtration column: blue
dextran (2,000 kDa) aldolase (158 kDa), bovine serum albumin
(67 kDa), ovalbumin (43 kDa), ribonuclease A (12.7 kDa) (GE
Healthcare). The elution position (Ve), column void volume (Vo),
and the bed volume of the column (Vt) were used to calculate K
average, defined as ([(Ve-Vo)/Vt-Vo)]), and plotted against the
logMW. The theoretical elution position for the monomeric,
dimeric, trimeric, and tetrameric forms of hHOGA are shown as
black squares. The elution position of recombinant hHOGA is
indicated by the green triangle.
(TIF)
Figure S3 Fit of the sedimentation equilibrium an-
alytical centrifugation data to monomer-dimer-tetramer
and dimer-tetramer models. Data obtained at 3 concentra-
tions and 2 rotor speeds were analyzed using the different
equilibria models and the HETEROANALYSIS and SEDPHAT
algorithms. The fits for the dimer-tetramer and monomer-dimer-
tetramer models are shown in the sold and dotted lines,
respectively. The calculated Kd values for the dimer-tetramer
equilibrium ranged from 58–63 mM.
(TIF)
Figure S4 Dynamic light scattering analysis of hHOGA.
Data were collected on a Malvern Zetasizer NanoS instrument
using a hHOGA concentration range from 0.25–25 mg mL
-1.
Inset: Plot of peak diameter versus protein concentration. The
theoretical diameter for the monomer, dimer, trimer, and tetramer
of hHOGA, assuming a spherical globular shape, are indicated by
the black squares.
(TIF)
Figure S5 Experimental electron density map and unit
cell packing. (A) Placement of the initial hHOGA model into the
2.10 A ˚ resolution, Hg
2+-phased experimental electron density map
contoured to 1.5 s (light blue). A contour of the map to 5 s (green)
highlights the Hg
2+ atom bound to Cys139. Atom colors are as
follows: light-orange, carbon atoms; blue, nitrogen; red, oxygen;
gray, mercury. (B) Orthogonal views of hHOGA packing within the
unitcell exhibitingP6422 symmetry.Each representative tetrameris
shown in shades of a different color. The asymmetric unit (a.s.u.) is
outlined with a dashed box and contains one monomer.
(TIF)
Figure S6 Representative kinetic analyses for the wild-
type and Y140F variants of hHOGA.
(TIF)
Acknowledgments
The authors thank Dr. Suzanna L. Bailey and the RapiData course staff at
the National Synchrotron Light Source (NSLS) beamline X25 for their
assistance during data collection. We are also grateful to Dr. Thomas Hollis
for assisting with data reduction and structure refinement.
Author Contributions
Conceived and designed the experiments: TJR LCJ RPH WTL.
Performed the experiments: TJR LCJ JK. Analyzed the data: TJR LCJ
JK RRH RPH WTL. Wrote the paper: TJR LCJ RPH WTL.
References
1. Jones JM, Morrell JC, Gould SJ (2000) Identification and characterization of
HAOX1, HAOX2, and HAOX3, three human peroxisomal 2-hydroxy acid
oxidases. J Biol Chem 275: 12590–12597.
2. Poore RE, Hurst CH, Assimos DG, Holmes RP (1997) Pathways of hepatic
oxalate synthesis and their regulation. Am J Physiol 272: C289–294.
3. Neims AH, Hellerman L (1962) Specificity of the D-amino acid oxidase in
relation to glycine oxidase activity. J Biol Chem 237: PC976–PC978.
4. Danupure C (2001) Primary hyperoxaluria. In: Scriver C, Beaudet A, Sly W,
Vallee D, Childs B, et al. (2001) The metabolic and molecular bases of inherited
disease, 8th edn. New York: McGraw-Hill. pp 3323–3367.
5. Phang JM, Hu CA, Valle D (2001) Disorders in proline and hydroxyproline
metabolism. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, et al. (2001)
The metabolic and molcular bases of inherited disease. 8th ed. New York:
McGraw-Hill. pp 1821–1838.
6. Kivirikko K (1970) Urinary excretion of hydroxyproline in health and disease.
Int Rev Conn Tiss Res 5: 93–163.
7. Valle D, Goodman SI, Harris SC, Phang JM (1979) Genetic evidence for a
common enzyme catalyzing the second step in the degradation of proline and
hydroxyproline. J Clin Invest 64: 1365–1370.
8. Adams E, Frank L (1980) Metabolism of proline and the hydroxyprolines. Annu
Rev Biochem 49: 1005–1061.
9. Hoppe B, Beck BB, Milliner DS (2009) The primary hyperoxalurias. Kidney Int
75: 1264–1271.
10. Holmes RP, Assimos DG (1998) Glyoxylate synthesis, and its modulation and
influence on oxalate synthesis. J Urol 160: 1617–1624.
11. Knight J, Jiang J, Assimos DG, Holmes RP (2006) Hydroxyproline ingestion and
urinary oxalate and glycolate excretion. Kidney Int 70: 1929–1934.
12. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, et al.
(2010) Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria
Type III. Am J Hum Genet 87: 392–399.
13. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges R, et al. (2011) Primary
hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor
for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6: 2289–2295.
14. Anderson M, Scholtz JM, Schuster SM (1985) Rat liver 4-hydroxy-2-
ketoglutarate aldolase: purification and kinetic characterization. Arch Biochem
Biophys 236: 82–97.
15. Dekker EE, Kitson RP (1992) 2-Keto-4-hydroxyglutarate aldolase: purification
and characterization of the homogeneous enzyme from bovine kidney. J Biol
Chem 267: 10507–10514.
16. Goldstone A, Adams E (1962) Metabolism of gamma-hydroxyglutamic acid. I.
Conversion to alpha-hydroxy-gamma-ketoglutarate by purified glutamic-aspar-
tic transaminase to rat liver. J Biol Chem 237: 3476–3485.
17. Maitra U, Dekker EE (1963) Enzymatic steps in the conversion of gamma-
hydroxyglutamate to glyoxylate and alanine. J Biol Chem 238: 3660–3669.
18. Rosso RG, Adams E (1967) 4-hydroxy-2-ketoglutarate aldolase of rat liver.
Purification, binding of substrates, and kinetic properties. J Biol Chem 242:
5524–5534.
19. Coulter-Mackie MB (2006) 4-Hydroxyproline metabolism and glyoxylate
production: A target for substrate depletion in primary hyperoxaluria? Kidney
Int 70: 1891–1893.
Human HOGA and Primary Hyperoxaluria Type 3
PLoS ONE | www.plosone.org 14 October 2011 | Volume 6 | Issue 10 | e2602120. Ruffo A, Testa E, Adinolfia, Pelizza G (1962) Control of the etric acid cycle by
glyoxylate. I. A new inhibitor of aconitase formed by the condensation of
glyoxylate with oxaloacetate. Biochem J 85: 588–593.
21. Kramer D, Klein N, Baselice R (1959) Quantitative determination of glyoxylic
acid. Anal Chem 31: 250–252.
22. Kobes RD, Dekker EE (1966) Beef liver 2-keto-4-hydroxyglutarate aldolase:
substrate stereospecificity and Schiff base formation with pyruvate and
glyoxylate. Biochem Biophys Res Commun 25: 329–334.
23. Cheriyan M, Toone EJ, Fierke CA (2007) Mutagenesis of the phosphate-binding
pocket of KDPG aldolase enhances selectivity for hydrophobic substrates.
Protein Sci 16: 2368–2377.
24. Fullerton SW, Griffiths JS, Merkel AB, Cheriyan M, Wymer NJ, et al. (2006)
Mechanism of the Class I KDPG aldolase. Bioorg Med Chem 14: 3002–3010.
25. Walters MJ, Srikannathasan V, McEwan AR, Naismith JH, Fierke CA, et al.
(2008) Characterization and crystal structure of Escherichia coli KDPGal aldolase.
Bioorg Med Chem 16: 710–720.
26. Blagova E, Levdikov V, Milioti N, Fogg MJ, Kalliomaa AK, et al. (2006) Crystal
structure of dihydrodipicolinate synthase (BA3935) from Bacillus anthracis at
1.94 A ˚ resolution. Proteins 62: 297–301.
27. Blickling S, Renner C, Laber B, Pohlenz HD, Holak TA, et al. (1997) Reaction
mechanism of Escherichia coli dihydrodipicolinate synthase investigated by X-ray
crystallography and NMR spectroscopy. Biochemistry 36: 24–33.
28. Devenish SR, Gerrard JA, Jameson GB, Dobson RC (2008) The high-resolution
structure of dihydrodipicolinate synthase from Escherichia coli bound to its first
substrate, pyruvate. Acta Crystallogr Sect F Struct Biol Cryst Commun 64:
1092–1095.
29. Kefala G, Evans GL, Griffin MD, Devenish SR, Pearce FG, et al. (2008) Crystal
structure and kinetic study of dihydrodipicolinate synthase from Mycobacterium
tuberculosis. Biochem J 411: 351–360.
30. Vistica J, Dam J, Balbo A, Yikilmaz E, Mariuzza RA, et al. (2004) Sedimentation
equilibrium analysis of protein interactions with global implicit mass conserva-
tion constraints and systematic noise decomposition. Anal Biochem 326:
234–256.
31. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al.
(2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
32. Guo BB, Devenish SR, Dobson RC, Muscroft-Taylor AC, Gerrard JA (2009)
The C-terminal domain of Escherichia coli dihydrodipicolinate synthase (DHDPS)
is essential for maintenance of quaternary structure and efficient catalysis.
Biochem Biophys Res Commun 380: 802–806.
33. Muscroft-Taylor AC, Catchpole RJ, Dobson RC, Pearce FG, Perugini MA,
et al. (2010) Disruption of quaternary structure in Escherichia coli dihydrodipi-
colinate synthase (DHDPS) generates a functional monomer that is no longer
inhibited by lysine. Arch Biochem Biophys 503: 202–206.
34. Pearce FG, Dobson RC, Weber A, Lane LA, McCammon MG, et al. (2008)
Mutating the tight-dimer interface of dihydrodipicolinate synthase disrupts the
enzyme quaternary structure: toward a monomeric enzyme. Biochemistry 47:
12108–12117.
35. Dobson RC, Valegard K, Gerrard JA (2004) The crystal structure of three site-
directed mutants of Escherichia coli dihydrodipicolinate synthase: further
evidence for a catalytic triad. J Mol Biol 338: 329–339.
36. Schuttelkopf AW, van Aalten DM (2004) PRODRG: a tool for high-throughput
crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr
60: 1355–1363.
37. Aisaka K, Igarashi A, Yamaguchi K, Uwajima T (1991) Purification,
crystallization and characterization of N-acetylneuraminate lyase from Escherichia
coli. Biochem J 276(Pt 2): 541–546.
38. Lawrence MC, Barbosa JA, Smith BJ, Hall NE, Pilling PA, et al. (1997)
Structure and mechanism of a sub-family of enzymes related to N-
acetylneuraminate lyase. J Mol Biol 266: 381–399.
39. Perugini MA, Griffin MD, Smith BJ, Webb LE, Davis AJ, et al. (2005) Insight
into the self-association of key enzymes from pathogenic species. Eur Biophys J
34: 469–476.
40. Maitra U, Dekker EE (1964) Purification and properties of rat liver 2-keto-4-
hydroxyglutarate aldolase. J Biol Chem 239: 1485–1491.
41. Scholtz JM, Schuster SM (1984) Substrates of hydroxyketoglutarate aldolase.
Bioorg Chem 12: 229–234.
42. Grady SR, Wang JK, Dekker EE (1981) Steady-state kinetics and inhibition
studies of the aldol condensation reaction catalyzed by bovine liver and
Escherichia coli 2-keto-4-hydroxyglutarate aldolase. Biochemistry 20: 2497–2502.
43. Samland AK, Sprenger GA (2006) Microbial aldolases as C-C bonding
enzymes–unknown treasures and new developments. Appl Microbiol Biotechnol
71: 253–264.
44. Griffiths JS, Cheriyan M, Corbell JB, Pocivavsek L, Fierke CA, et al. (2004) A
bacterial selection for the directed evolution of pyruvate aldolases. Bioorg Med
Chem 12: 4067–4074.
45. Wymer N, Buchanan LV, Henderson D, Mehta N, Botting CH, et al. (2001)
Directed evolution of a new catalytic site in 2-keto-3-deoxy-6-phosphogluconate
aldolase from Escherichia coli. Structure 9: 1–9.
46. Theodossis A, Walden H, Westwick EJ, Connaris H, Lamble HJ, et al. (2004)
The structural basis for substrate promiscuity in 2-keto-3-deoxygluconate
aldolase from the Entner-Doudoroff pathway in Sulfolobus solfataricus. J Biol
Chem 279: 43886–43892.
47. Pauluhn A, Ahmed H, Lorentzen E, Buchinger S, Schomburg D, et al. (2008)
Crystal structure and stereochemical studies of KD(P)G aldolase from
Thermoproteus tenax. Proteins 72: 35–43.
48. Soares da Costa TP, Muscroft-Taylor AC, Dobson RC, Devenish SR,
Jameson GB, et al. (2010) How essential is the ’essential’ active-site lysine in
dihydrodipicolinate synthase? Biochimie 92: 837–845.
49. Dobson RC, Perugini MA, Jameson GB, Gerrard JA (2009) Specificity versus
catalytic potency: The role of threonine 44 in Escherichia coli dihydrodipicolinate
synthase mediated catalysis. Biochimie 91: 1036–1044.
50. Dobson RC, Devenish SR, Turner LA, Clifford VR, Pearce FG, et al. (2005)
Role of arginine 138 in the catalysis and regulation of Escherichia coli
dihydrodipicolinate synthase. Biochemistry 44: 13007–13013.
51. Danpure CJ (2005) Molecular etiology of primary hyperoxaluria type 1: new
directions for treatment. Am J Nephrol 25: 303–310.
52. Lumb MJ, Birdsey GM, Danpure CJ (2003) Correction of an enzyme trafficking
defect in hereditary kidney stone disease in vitro. Biochem J 374: 79–87.
53. Pflugrath JW (1999) The finer things in X-ray diffraction data collection. Acta
Crystallogr D Biol Crystallogr 55: 1718–1725.
54. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallogr D Biol Crystallogr 66: 213–221.
55. Brunger AT (2007) Version 1.2 of the Crystallography and NMR system. Nat
Protoc 2: 2728–2733.
56. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development
of Coot. Acta Crystallogr D Biol Crystallogr 66: 486–501.
57. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystal-
logr 53: 240–255.
58. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, et al.
(2010) MolProbity: all-atom structure validation for macromolecular crystallog-
raphy. Acta Crystallogr D Biol Crystallogr 66: 12–21.
Human HOGA and Primary Hyperoxaluria Type 3
PLoS ONE | www.plosone.org 15 October 2011 | Volume 6 | Issue 10 | e26021